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Abstract
Background: The aims were to explore bone mineral density (BMD) by digital X-ray radiogrammetry (DXR) in
postmenopausal women with long-lasting rheumatoid arthritis (RA) in relation to dual x-ray absorptiometry (DXA)-
BMD, joint destruction by conventional radiographs and disease related variables in a cross-sectional study.
Methods: Seventy-five postmenopausal women with RA were examined by DXA measuring DXA-BMD of the
forearm, total hip and lumbar spine, by scoring joint destruction on plain radiographs by the method of Larsen
and by DXR-BMD in metacarpals two to four. The DXR-BMD results of the RA women were compared with an age
and sex-matched reference database. A function of DXR-BMD in relation to age and disease duration was created.
Associations were investigated by bivariate and multiple linear regression analyses.
Results: DXR-BMD was strongly decreased in RA patients compared to the reference database (p < 0.001).
Calculations showed that DXR-BMD was not markedly influenced the first years after diagnosis of RA, but between
approximately 5-10 years of disease there was a steep decline in DXR-BMD which subsequently levelled off. In
multiple regression analyses disease duration, CRP and DXR-BMD were independent variables associated with
Larsen score (R
2= 0.64). Larsen score and BMD forearm were independent determinants of DXR-BMD (R
2 = 0.79).
Conclusions: DXR-BMD was strongly reduced and associated with both Larsen score and DXA-BMD forearm in
these postmenopausal women with RA implying that DXR-BMD is a technique that reflects both the erosive
process and bone loss adjacent to affected joints.
Background
Rheumatoid arthritis (RA) is a common inflammatory
rheumatic disease characterized by synovitis and by
development of cartilage destruction in the joints, ero-
sions in the subchondral bone at the joint margins and
by periarticular osteopenia adjacent to inflamed joints
[1,2]. In addition, generalized osteoporosis affecting the
axial and appendicular bones is a well-known phenom-
enon in RA as demonstrated by decreased bone mineral
density (BMD) in several studies [3-5]. Also, the risk of
fractures in RA is elevated [6-8].
Conventional radiographs are the standard method for
detection and quantificationo fj o i n td e s t r u c t i o ni nR A
[9,10]. However, the disadvantages of conventional ima-
ging are its limited sensitivity in early joint space nar-
rowing and periarticular osteoporosis. Bone loss less
than around 30% cannot be detected on plain radio-
graphs [11]. The scoring systems are also time consum-
ing, and suitable in particular for experts.
Radiograph-assessed cortical bone width as a measure
of bone strength and bone loss was proposed in 1960
using radiographs of the hand bones [12,13]. Refinement
in radiogrammetry increased its precision and the devel-
opment of automated algorithms for image assessment
has led to an increased interest in the technique [14]. In
RA, localized bone involvement in the hands can be
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gives an estimate of cortical hand BMD in the metacar-
pals two to four. Quantification of the localized periarti-
cular osteoporosis has been proposed to be an outcome
measure in monitoring treatments in early RA [15,16]
and to be able to predict future radiographic joint
damage [17-19]. Localized bone loss in early RA has
been found to be better detected by DXR-BMD than by
dual x ray absorptiometry (DXA) - BMD [20]. DXR-
BMD may also be used in fracture risk assessment [21].
So far, there is limited knowledge of DXR-BMD in
long-standing RA, but interestingly, Haugeberg et al
found in 2004 that DXR-BMD was a strong indicator of
joint damage and of vertebral and non-vertebral fracture
risk in RA women with disease duration of ≥ 5 years [22].
The aims of this cross-sectional study were to explore
DXR-BMD in postmenopausal women with established
RA in relation to DXA-BMD, radiological joint destruc-
tion, measures of disease activity and functional status.
Methods
Patients
Eighty-eight postmenopausal women with RA aged
between 45-65 years were included in a trial which has
been described previously [23]. Patients had an active dis-
ease which met at least two of the following criteria: at
least 6 painful, at least 3 swollen joints out of 28, erythro-
cyte sedimentation rate (ESR) >20 mm/h and C-reactive
protein (CRP) >10 mg/L. A maximum daily dose of 7.5
mg of prednisolone was accepted. Patients fulfilled the
American Rheumatism Association 1987 revised criteria
for adult RA [24]. DXR-BMD was assessed in 75 women
out of the 88 women who were included in the trial. As a
consequence of prostheses, osteosynthetic materials and
the position of the hands it was not possible to measure
DXR-BMD on all radiographs of the 88 women. Thus,
this report presents results of the 75 RA women.
Assessment of outcome variables
Disease Activity was assessed by the Disease Activity
Score 28 (DAS 28) [25].
Physical disability was evaluated by the Health Assess-
ment Questionnaire (HAQ) where 0 implies no handi-
cap and 3, severe disability [26,27].
Radiographs of the hands, wrists and forefeet were
obtained. Forty joints in the hands and feet were scored.
(in the hands, proximal interphalangeal joints of digits
1-5, metacarpophalangeal joints of digit 1-5, wrist areas
1-4, in the feet the interphalangeal joints of digit 1 and
the metatarsophalangeal joints of digit 1-5). Larsen
score was evaluated by Dr Arvi Larsen [28]. Each joint
was scored from 0 (normal) to 5 (maximal destruction).
The scores for every patient were summarised and
divided by the number of examined joints to give the
mean Larsen score ranging from 0-5. Larsen score
obtained from the hands and wrists but not from the
forefeet are also given. Erosive disease is defined as a
score of at least 2 in at least one joint.
DXR-BMD was measured on standard radiographs of
the hands by a computer version (dxr-online, Sectra,
Linköping, Sweden) [29] of the traditional technique of
radiogrammetry [12]. The computer automatically
recognises regions of interest around the narrowest part
of the second, third and fourth metacarpal bones of the
hands. In each region the cortical thickness and bone
width are measures 90-204 times per centimeter. The
final BMD estimate is defined as : DXR-BMD = c ×
VPAmc × (1-p) where c is a constant (determined such
that DXR-BMD on average is equal to the mid-distal
forearm region of the Hologic QDR-2000 device (Holo-
gic, Waltham, MA, USA)). VPA is the volume per pro-
jected area and p is porosity [29].
The mean values of DXR-BMD from left and right
hands were used when both radiographs were available.
Sixty-three out of 75 values are mean DXR-BMD, 9 left
and 3 right hand values. The value of these 75 measure-
ments is given when not indicated otherwise.
The results of DXR-BMD in left hand in our patients
was compared with DXR-BMD measured in the non-
dominant hand in a large normative reference database
comprising of 822 North American Caucasian Females,
20 - 79 years old [30]. Our findings of DXR-BMD are
presented as absolute values (g/cm
2). Z-score, which is
related to the normative reference database, is also given
of the left hand.
A function of DXR-BMD in relation to age and disease
duration
A function of Z-score was formed based on results of
the individual patients Z-score, age and disease duration.
In order to find out if Z-score was influenced differently
depending on diverse intervals of disease duration a
piece-wise linear regression with break points at the
duration of 5 and 10 years was obtained.
DXA-BMD at left total forearm, left total hip and lumbar
spine (L1-4) was measured by DXA, Hologic QDR-4500A
(Hologic Inc., Bedford, MA, USA). The in-vivo precisions
were found to be 0,4% both at the lumbar spine and total
hip and according to the manufacturer the in-vivo preci-
sion of DXA of the forearm was <1%. It was not possible
to measure all skeletal sites in every patient due to pre-
sence of prostheses and osteosynthetic materials. The
results are presented as absolute values (g/cm
2)a n dZ -
scores, related to sex and age matched references.
Biochemical analyses of blood samples
Venous blood samples were drawn in the morning after an
overnight fast and stored at -70°C until time of analysis.
Routine laboratory tests: erythrocyte sedimentation
rate (ESR), C-reactive protein (CRP), Haemoglobin (Hb)
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standard laboratory techniques.
Carboxyterminal telopeptide fragments of type I collagen
Serum levels of bone resorption derived collagen type I
fragments (CTX-I) was measured by a one step ELISA
(Nordic Bioscience A/S, Herlev, Denmark) [31]. The
detection limit was 0.01 ng/mL. Intra- and inter-assay
coefficient of variations (CV) of the serum CTX-I assay
was 5.4 and 6.2% respectively.
Carboxyterminal telopeptide of type I collagen
Radioimmunoassay (RIA) was used for the quantitative
determination in serum of the bone resorption marker
ICTP (Orion Diagnostica, Espoo, Finland). The detec-
tion limit of the test was 0.5 ng/mL and the intra- and
inter-assay CV were <8% according to the manufacturer
and <6% at our laboratory.
Ethical aspects
All patients gave informed written consent according to
the Declaration of Helsinki. The study was approved by
the Regional Ethics Committee in Gothenburg, R528-97.
Statistics
Analyses were performed using SPSS version 16.0 (SPSS
Inc., Chicago, IL). Descriptive statistics are presented as
mean and standard deviations (SD). Bivariate correla-
t i o n sw e r ea s s e s s e db yP e a r s o n ’s Correlations (r) and by
Spearman’s Correlation (rs) when appropriate. Multiple
linear regression analyses were used by a stepwise (for-
ward) method to explore the relationships between
DXR-BMD, DXA-BMD forearm, Larsen score and Lar-
sen score (hand) as dependent variables and the demo-
graphic and disease related variables listed in Table 1,
which had shown significant correlations in the simple
regressions. All tests were two tailed and p < 0.05 was
considered statistically significant.
Results
Patients
In table 1, characteristics of the patients are displayed.
All women were postmenopausal. The mean age at
menopause was 49.1 ± 3.5 years and the mean time
since menopause was 8.4 ± 5.7 years. Disease modifying
anti rheumatic drugs (DMARD) were used by 85%.
Methorexate was the most common DMARD used by
28 (37%) women. Low-dose prednisolone was used by
18 (24%) patients, 1.25. mg to 7.5 mg/day. Sixty-three
out of 75 (88%) had an erosive disease and 61 (81%) had
positive tests for RF.
DXR-BMD in RA women in comparison with reference
population
DXR-BMD was compared with a normative reference
database [30]. The Z-score, non dominant hand, of the
female general population has the mean 0 and the stan-
dard deviation 1. The mean Z score of the RA women,
left hand, was -2.27 ± 1.69 SD, much lower than zero of
the DXR manufactures reference population (p < 0.001).
DXR-BMD in relation to age and disease duration
A function of Z-score was formed based on results of
the individual patients Z-score, age and disease duration.
Z-score = -0.315 - 0.0155⋅age - 0.0702⋅duration (multi-
ple correlation coefficient 0.49).
The function demonstrates that disease duration has a
much larger and significant impact on Z-score as com-
pared to age of the patients. Therefore, the independent
variable age was excluded and a linear regression com-
prising disease duration as the only independent variable
was formed.
Z-score = -1.193 - 0.0712⋅duration (correlation coeffi-
cient -0.49, p < 0.001).
Table 1 Characteristics of the patients
n Characteristics
Age, years 75 57.6 ± 5.2
Height, cm 75 163.2 ± 6.4
Weight, kg 75 67.2 ± 12.7
Disease duration, years 75 14 (7, 20)
Disease modifying anti rheumatic drugs ( n, %) 75 64, 85%
Glucocorticosteroid treatment ( n, %) 75 18, 24%
Health Assessment Questionnaire, score 75 1.00 (0.38, 1.50)
Disease Activity Score 28, score 74 5.3 ± 1.0
Haemoglobin,(g/L 75 129 ± 12
Erythrocyte sedimentation rate, mm/h 74 28 ± 17
C-reactive protein, mg/L 74 17 ± 17
Mean Larsen score, score 72 1.21 ± 0.96
Mean Larsen score, hands, score 72 1.18 ± 1.02
DXA-BMD, forearm, g/cm
2 70 0.47 ± 0.10
DXA-BMD, forearm, Z-score 70 -0.59 ± 1.94
DXA-BMD, total hip, g/cm
2 74 0.78 ± 0.15
DXA-BMD, total hip, Z-score 74 -0.69 ± 1.21
DXA-BMD, lumbar spine, g/cm
2 74 0.86 ± 0.13
DXA-BMD, lumbar spine, Z-score 74 -0.44 ± 1.14
DXR-BMD, left hand, g/cm
2 72 0.45 ± 0.08
DXR-BMD, right hand, g/cm
2 66 0.46 ± 0.09
DXR-BMD, mean values, g/cm
2 63 0.46 ± 0.08
DXR-BMD, mean, left or right hand, g/cm
2 75 0.45 ± 0.09
CTX-I, ng/mL 68 0.61 ± 0.36
ICTP, ng/mL 66 4.9 ± 1.9
Demographic variables, clinical and laboratory measurements of disease
activity, radiographic score (Larsen), bone mineral density measurements by
dual energy x-ray absorptiometry and by digital x-ray radiogrammetry in
postmenopasusal women with RA.
Values are means ± SD or median (IQR) when not stated otherwise, n =
number of patients with available data.
CTX-I = C-terminal telopeptide fragments of type I collagen, ICTP = C-terminal
telopeptide of type I collagen
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enced differently depending on diverse intervals of dis-
ease duration a piece-wise linear regression with break
points at the duration of 5 and 10 years was obtained.
Z-score = -0.6796 + 0.0028⋅min(duration, 5) -
0.4177⋅max(min(duration-5, 10-5), 0) -0.0209⋅max(dura-
tion-10, 0) (multiple correlation coefficient 0.60).
The correlation coefficient in the last function is
higher compared with the previous coefficients, indicat-
ing a better explanation for the Z-score in the last
model. The function shows that during the first years
after diagnosis of RA the Z-score is not markedly influ-
enced, but between approximately 5-10 years of disease
there is a steep decline in DXR-BMD which subse-
quently levels off (Figure 1).
From the last relationship we found that the mean Z-
score at diagnosis was -0.68. Furthermore, we calculated
that the probability to have a Z-score larger than 0 at
diagnosis was 31%. Thus, at diagnosis the DXR-BMD did
not differ so much from that of the general population.
Associations between DXR-BMD, DXA-BMD, Larsen score
and markers of inflammation and bone turnover
DXR-BMD in left and right hand correlated strongly (r =
0.93). Both DXR-BMD in left hand and in right hand cor-
related strongly with mean value of left and right hand
DXR-BMD (r = 0.98). The mean DXR value in the right
hand was 0.46 g/cm
2 and in the left 0.45 g/cm
2, p = 0.053.
Associations between DXR-BMD, DXA-BMD, Larsen
score and markers of inflammation and bone turnover
a r es h o w ni nt a b l e2 .D X R -B M Dw a ss i g n i f i c a n t l y
strongly inversely correlated to Larsen score which is
illustrated in Figure 2.
Multiple regression analyses
Results of the multiple regression analysis with DXR-
BMD, Larsen score, Larsen score hand and DXA-BMD
forearm are shown in Table 3. In the analysis with DXR-
BMD as the dependent variable Larsen score and BMD
forearm were found to be significant independent determi-
nants (R
2 = 0.79). If only the BMD measure sites, lumbar
spine and hip, that are used in clinical practice evaluating
t h ep r e v a l e n c eo fo s t e o p e n i a / osteoporosis were put into
the model, we found that Larsen score (hand), BMD lum-
bar spine, age and weight were significant independent
variables connected with DXR-BMD (R
2 = 0.66). Finally,
BMD total hip, BMD lumbar spine and DXR-BMD were
independent variables connected with, DXA-BMD fore-
arm (R
2= 0.76). If DXR-BMD was excluded from the ana-
lyse BMD total hip and lumbar spine, Larsen score (hand)
and age were significant independent variables connected
with DXA-BMD forearm (R
2 = 0.70)
Discussion
In this group of postmenopausal women with long-term
RA, we found, for the first time, that DXR-BMD was
significantly and markedly reduced, Z-score -2.27 ±
1.69SD compared to the reference population. The
DXR-BMD Z-score was numerically notably lower com-
pared to the DXA-BMD Z-scores in our trial showing
Z-score of -0.59 ± 1.94SD in forearm, -0.69 ± 1.21SD in
total hip and -0.44 ± 1.14SD in lumbar spine. The find-
ing indicates that the cortical BMD in the metacarpal
bones is more influenced by RA as compared to BMD
assessed by DXA which measures both cortical and tra-
becular BMD. The DXA-BMD findings are in line with
previous results of BMD assessed by DXA in RA dis-
playing reduced DXA-BMD [4,5,32].
Furthermore, our estimations showed that DXR-BMD
was marginally reduced at start of the RA disease and
the largest decrease was approximate during 5-10 years
after RA debuted. Previous investigations have found
decrease in DXR-BMD the first years after RA diagnose
[17,18,20,33] and Böttcher et al, who followed RA
patients during 6 years, showed a continuous decrease
in DXR-BMD [34]. Hoff et al found a reduction of
DXR-BMD during 2-years follow-up in both patients
with disease duration < 3 years and > 3 years [35]. Jen-
s e ne ta lf o u n d ,i nas t u d yi n v e s t i g a t i n gD X R - B M D
between groups of RA women stratified according to
disease duration, significantly lower DXR-BMD in RA
women with disease duration ≥ 10 years compared with
patients with disease duration < 2years but not with
patients with disease duration between 2 and 10 years
[36]. In our study, exclusively women were included.
The mean age was 58 years, the mean disease duration
was 15 years and the mean age at menopause was 49
years in our trial. Thus, the mean age when RA debuted
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Figure 1 DXR-BMD in relation to disease duration. The mean Z-
score (SD) of the patients was estimated as piece-wise linear and
continuous function of the disease duration. The corresponding
function for the general population coincides with the x-axes. (Z-
score = -0.6796 + 0.0028 min(duration, 5) - 0.4177 max(min
(duration-5, 10-5), 0) -0.0209 max(duration-10, 0) (multiple
correlation coefficient 0.60)).
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Page 4 of 8Table 2 Correlations. Correlations between bone mineral density by digital X-ray radiogrammetry and by dual energy x-ray absorptiometry, total Larsen
score, Larsen score of the hands, markers of inflammation and bone turnover in postmenopausal women with rheumatoid arthritis
Age Height Weight Disease
duration
HAQ DAS
28
ESR CRP Hb CTX-I ICTP DXR-
BMD
Larsen
score
Larsen
score hand
DXA-BMD
forearm
DXA-BMD
total hip
DXA-BMD
lumbar spine
DXR-BMD -0.33**
(75)
0.31**
(75)
0.38**
(75)
-0.45***
(75)
-0.29*
(75)
-0.20
(74)
-0.32**
(74)
-0.21
(74)
0.31**
(75)
-0.22
(68)
-0.28*
(66)
-0.68***
(72)
-0.68*** (72) 0.82*** (70) 0.65*** (74) 0.52*** (74)
Larsen
score
0.002
(72)
-0.13
(72)
-0.20
(72)
0.46***
(72)
0.42***
(72)
0.33**
(71)
0.55***
(71)
0.49***
(71)
-0.39***
(72)
0.29*
(66)
0.61***
(63)
-0.68***
(72)
0.97*** (72) -0.48*** (67) -0.43*** (71) -0.17
(71)
Larsen
score, hand
0.022
(72)
-0.14
(72)
-0.14
(72)
0.48***
(72)
0.46***
(72)
0.33**
(71)
0.54***
(71)
0.48***
(71)
-0.36***
(72)
0.32**
(66)
0.65***
(63)
-0.68***
(72)
0.97***
(72)
-0.50*** (67) -0.42*** (71) -0.20
(71)
DXA-BMD
forearm
-0.32**
(70)
0.35**
(70)
0.46***
(70)
-0.34** (70) -0.16
(70)
-0.040
(69)
-0.082
(69)
-0.07
(69)
0.16
(70)
-0.16
(63)
-0.23
(62)
0.82***
(70)
-0.48***
(67)
-0.50*** (67) 0.76*** (69) 0.69*** (69)
Number of patients with available data is given within (). *p < 0,05, **p < 0,01, ***p < 0,001
CTX-I = C-terminal telopeptide fragments of type I collagen, ICTP = C-terminal telopeptide of type I collagen
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8was 43 years in this group of RA women. The largest
fall in DXR-BMD was between 5 and 10 years after the
disease started, accordingly between the ages of 48 and
53 years, coinciding with the years surrounding meno-
pause. During this period the production of estradiol
diminishes which is associated with accelerated bone
loss [37]. The fast decrease in DXR-BMD was based on
Z-scores, excluding the influence of menopause as the
only cause, although, it could be hypothesised that RA
women are more sensitive to menopause and its hormo-
nal alteration concerning influence on disease process
and BMD compared to the general population. In accor-
dance, treatment with HRT has been found to increase
BMD, retard joint destruction as well as reduce disease
activity [23,38,39]. In addition, we recently found that
treatment with HRT stabilised DXR-BMD in postmeno-
pausal RA [40]. Interestingly, also the peak incidence of
RA onset corresponds with the years surrounding the
menopause when serum levels of estradiol fall [41,42].
There was a tendency of significantly higher DXR-
BMD values in the right hand as compared with the left
hand although the correlation between right and left
hand DXR-BMD values was very high (0.93) in accor-
dance with others [36].
DXR-BMD was strongly associated with Larsen score
evaluated on hands and feet and on hands only. DXR-
BMD was also strongly correlated to BMD measured by
DXA, in particular in the forearm, also found by Black et
al who obtained correlations between DXR-BMD and
DXA-BMD at the wrist of 0.90 and of 0.61 at the hip [30].
In multiple regression analyses Larsen score and BMD
forearm remained the most important independent
determinants of DXR-BMD displaying a high R
2 value
whereas DXR-BMD, ESR and disease duration were
associated with Larsen score. Based on these results,
DXR-BMD seems to be a technique that reflects radio-
graphic joint destruction powerfully and at the same
time, bone loss both in the axial and appendicular skele-
ton, in agreement with others [36,43].
To assess radiographic joint destruction by traditional
validated scoring system is time consuming and suitable
in particular for experts. In contrast DXR-BMD is an
objective and convenient digitalized method quantifying
localized bone-loss. Thus, DXR-BMD has been proposed
to be an outcome measure in monitoring treatments in
early RA [15,16] and have been found to be able to pre-
dict future radiographic joint damage [17-19]. The role
of DXR-BMD in predicting progressive joint destruction
in established RA remains to be explored. Recently,
Book et al found that low DXR-BMD in RA patients
Table 3 Multiple regression analyses
DXR-BMD Larsen score Larsen score hand DXA-BMD forearm
Constant 0.28 2.74 2.22 -0.12
Beta SE P Beta SE P Beta SE P Beta SE P
Disease duration (years) 0.020 0.007 0.005 0.022 0.007 0.003
CRP (mg/L) 0.017 0.004 <0.001 0.014 0.005 0.010
ICTP (ng/mL) 0.092 0.049 0.064
DXR-BMD (g/cm
2) -4.81 0.96 <0.001 -4.74 0.99 <0.001 0.62 0.097 <0.001
Larsen score (score) -0.049 0.007 <0.001
BMD forearm (g/cm
2) 0.47 0.057 <0.001
BMD total hip (g/cm
2) 0.15 0.072 0.039
BMD lumbar spine (g/cm
2) 0.23 0.071 0.002
R
2 0.79 0.67 0.70 0.76
Multiple regression analyses of bone mineral density by digital x-ray radiogrammetry and by dual energy x-ray absorptiometry and of joint destruction assessed
by Larsen score in postmenopausal women with rheumatoid arthritis.
Beta values are unstandardized coefficients. The R
2 is the total variance explained in the model. SE = standard error
ICTP = C-terminal telopeptide of type I collagen
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Figure 2 Relation between joint destruction and DXR-BMD.
Scatter diagrams of mean Larsen score and bone mineral density
by digital X-ray radiogrammetry. The regression line is inserted and
Pearson’s Correlation (r) is given.
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Page 6 of 8predicted overall mortality, which supports DXR-BMD
as a promising prognostic tool [44]. Also, it remains to
be elucidated in long-lasting RA, if the technique is sui-
table to be used as a disease outcome measure in clini-
cal trials and in ordinary clinical practice evaluating the
effects of DMARDs on the peripheral skeleton. Thus,
further prospective longitudinal studies of the role of
DXR-BMD in established RA are needed. Another intri-
guing question is if drugs that target different biological
mechanisms affect DXR-BMD diversely or not.
Conclusions
We have found, in these postmenopausal women with
RA that DXR-BMD was markedly decreased. In multiple
regression analyses, Larsen score was strongly associated
with DXR-BMD and DXR-BMD was strongly connected
with both Larsen score and DXA-BMD implying that
DXR-BMD is a method that in particular reflects the
erosive process in addition to bone loss adjacent to
affected joints.
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